Michael S. Grimley, MD

The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Schuster, JE; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Stewart, LS; Stahl, A; Potter, M; Rahman, H; et al. Clinical Infectious Diseases. 2024; 78:217-226.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Anand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Transplant Infectious Disease. 2023; 25:e14179.

Preliminary Results of a Phase 2a Clinical Trial to Evaluate Safety, Tolerability and Antiviral Activity of Intravenous Brincidofovir (BCV IV) in Immunocompromised Patients with Adenovirus Infection. Grimley, M; Maron, G; Gomez, CA; Prasad, VK; Dara, J; Papanicolaou, GA; Fukushima, K; Wynn, RF; Boeckh, M. Blood. 2023; 142:112.

Immunogenicity and Safety of Alternative Influenza Vaccination Strategies in Repeated Seasons in Pediatric Hematopoietic-Cell Transplant Recipients. Bahakel, H; Spieker, AJ; Stahl, A; Rahman, H; Amarin, J; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; et al. Journal of the Pediatric Infectious Diseases Society. 2023; 12:s21.

Reduced-intensity conditioning mitigates risk for primary ovarian insufficiency but does not decrease risk for infertility in pediatric and young adult survivors of hematopoietic stem cell transplantation. JD, B; H, OT; J, B; JC, H; P, B; SM, D; MS, G; S, J; C, P; K, B; et al. 2023.

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Takahashi, T; Al-Kofahi, M; Jaber, M; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Neuberg, DS; Choi, SW; Davis, J; et al. Blood. 2023; 142:700-710.

Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Montiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; et al. Pediatric Blood and Cancer. 2023; 70:e30429.

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Galletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; et al. Transplantation and cellular therapy. 2023; 29:305-310.

Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; et al. The Pediatric Infectious Disease Journal. 2023; 42:119-121.

Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Bender, JD; Oquendo-del Toro, H; Benoit, J; Howell, JC; Badia, P; Davies, SM; Grimley, MS; Jodele, S; Phillips, C; Burns, K; et al. Transplantation and cellular therapy. 2023; 29:130.e1-130.e8.